Am J Transplant, Volume 18, Suppl 3 Archives - Page 141 of 211 - ATC Abstracts

2018 American Transplant Congress
Patient-Centered Outcomes after Liver Transplantation: A Qualitative Study
G. Lee, J. Obayemi, E. Rubin.
Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA; Medicine, Massachusetts General Hospital, Boston, MA.
Introduction: Outcomes after liver transplantation are most commonly reported by medical professionals as rates of graft failure, episodes of acute rejection, length of hospital stay,…
2018 American Transplant Congress
Survival, Cancer and PTLD Diagnosis after Late EBV Infection in Adult Kidney Transplantation
M. Morton,¹ G. Scullin,² K. Daga,² P. Klapper,² P. Vallely,² M. Picton.¹
¹Department of Renal Medicine, Manchester Royal Infirmary, Manchester, United Kingdom; ²Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
Introduction: While EBV seronegative recipients have a high risk of early PTLD knowledge is lacking regarding the implications of EBV DNAemia in stable patients in…
2018 American Transplant Congress
Predicting Outcomes of Rat Vascularized Composite Allotransplants through Quantitative Measurement of Chimerism with PCR-Amplified Short Tandem Repeat
H. Cheng,¹ X. Huang,² C-.F. Lin,¹ N. AL Deek,² L. Shih,² C-.H. Lin,^1,2 F-.C. Wei.^1,2,3
¹Center for Vascularized Composite Allotransplantation, Linkou Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Linkou Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan; ³College of Medicine, Chang Gung University, Gueishan, Taoyuan, Taiwan.
Background: Chimerism, defined as coexistence of donor and recipient cells, has been associated with induction and maintenance of tolerance to allotransplants. Although most studies have…
2018 American Transplant Congress
The Novel Polymer Pro-Drug APP-103 Reduces I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model
K. Minami,^1,3 H. Uehara,^1,3 A. Elkhal,^1,3 A. Weins,³ S. Bae,^2,3 J. Reder,⁴ B. Houser,⁴ P. Kang,^2,3 S. Tullius.^1,3
¹Transplant Surgery Division, Department of Surgery, Brigham and Women's Hospital, Boston, MA; ²Beth Israel Deaconess Medical Center, Boston, MA; ³Harvard Medical School, Boston, MA; ⁴Celdara Medical, LLC, Lebanon, NH.
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…
2018 American Transplant Congress
Lower Incidence of De Novo Donor-Specific Antibodies against HLA-DR in ABO-Incompatible Renal Transplantation
M. Okada,¹ K. Futamura,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ Y. Watarai,¹ K. Iwasaki,² T. Kobayashi.²
¹Department of Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Department of Transplant Surgery, Aichi Medical University, Nagakute, Japan.
IntroductionDe novo DSA-induced chronic antibody-mediated rejection (AMR) is one of major obstacles to long term graft survival. We have reported that anti-A/B antibody binding could…
2018 American Transplant Congress
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts
M. Everly,¹ V. Jucaud,¹ M. Roberts,² H. Gebel,³ R. Bray.³
¹Terasaki Research Institute, Los Angeles, CA; ²Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; ³Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…
2018 American Transplant Congress
10-Year Outcomes of Renal Transplantation from Circulatory Death Donors with Increased Terminal Creatinine
Y. Tomita, K. Iwadoh, I. Nakajima, S. Fuchinoue.
Surgery III, Tokyo Women's Medical University, Tokyo, Japan.
Background: To alleviate chronic renal graft shortages in Japan, donation after circulatory death (DCD) is an increasingly used organ resource. Organs from DCD donors with…
2018 American Transplant Congress
De Novo or Early Conversion to Everolimus and the Risk of Skin Cancers in Kidney Transplant Recipients: A Trial-Based Linkage Study
T. Ying,^1,2 G. Wong, W. Lim, G. Russ, H. Pilmore, J. Kanellis, D. Goodman, P. Trevillian, S. Campbell, M. Suranyi, M. Mathew, R. Faull, R. Masterson, R. Walker, P. O'Connell, S. Chadban.^1,2
¹Renal Medicine, Royal Prince Alfred Hospital, Camperdown, Australia; ²Kidney Node, Charles Perkins Centre, University of Sydney, Camperdown, Australia.
Introduction: Non-melanoma skin cancers (NMSC) are a significant cause of morbidity in kidney transplant (KT) recipients. Choice of immunosuppressive regimen may modify the risk of…
2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
Y. Matsuoka,¹ K. Iwasaki,² Y. Miwa,² K. Horimi,¹ K. Uchida,² T. Kobayashi.¹
¹Renal Transplant Surgery, Aichi Medical University, Nagakute City, Aichi, Japan; ²Kidney Disease and Transplant Immunology, Aichi Medical University, Nagakute City, Aichi, Japan.
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…
2018 American Transplant Congress
Transplant Cost Reduction in a Developing Country: “The Case of Guatemala”
S. Méndez,¹ B. Remey,² E. Reyes,¹ A. Aguilar-González,¹ R. Lou-Meda.¹
¹Servicio de Nefrología, Hipertensión, Diálisis y Trasplante Hospital Roosevelt/FUNDANIER, Guatemala, Guatemala; ²Department of Pharmaceutical Chemistry, Universidad del Valle de Guatemala, Guatemala, Guatemala.
Background: Guatemala, south-west of Mexico has a population of approximately 16 million people of which 60% are younger than 20 years. As any other developing…